Bausch Health Companies Inc. and its gastroenterology division, Salix Pharmaceuticals, announced findings from an analysis of Xifaxan® (rifaximin) monotherapy, which will be presented at the Presidential Plenary Session of The American College of Gastroenterology’s 2024 Annual Scientific Meeting in Philadelphia. This analysis, stemming from two randomized trials, assessed the effectiveness of Xifaxan monotherapy against lactulose monotherapy in reducing the recurrence of overt hepatic encephalopathy (OHE) and mortality.
At the meeting, Salix will also unveil data regarding the influence of Xifaxan on rehospitalization rates post-OHE discharge in both commercially insured and Medicare patient groups.
Additionally, two posters will report on the efficacy of Plenvu® as a bowel preparation medication, specifically in colonoscopy patients with comorbid conditions or those on medications affecting bowel prep quality.
Aimee Lenar, Executive Vice President of US Pharma at Bausch Health, remarked that these presentations might bolster healthcare professionals’ confidence in Salix’s treatments, which aim to enhance patient outcomes. She emphasized Bausch Health’s commitment to developing impactful solutions and expanding evidence for its medications.
The research and analyses from Salix to be featured at ACG 2024 include:
XIFAXAN:
An analysis by Bajaj, Jasmohan S., et al., indicating that rifaximin monotherapy surpasses lactulose monotherapy in mitigating OHE recurrence and overall mortality.
- Scheduled for Presentation #9 at the Presidential Plenary Session 2 on October 28, 10:06 – 10:18 AM ET.
- Research by Jesudian, Arun B., et al., on rifaximin’s impact on OHE rehospitalizations post-discharge in both commercially insured and Medicare patients.
PLENVU:
- Findings by Cash, Brooks D., et al., and Poppers, David., et al., demonstrating the efficacy and safety of the 1-Liter NER1006 bowel preparation for colonoscopy in patients with conditions or medications influencing prep quality.
About XIFAXAN:
XIFAXAN is employed for reducing the risk of OHE recurrence in adults and treating irritable bowel syndrome with diarrhea in adults. It is contraindicated for patients with hypersensitivity to rifaximin or its components. Various safety concerns, adverse reactions, and interactions with other medications, such as warfarin and P-gp inhibitors, are highlighted.
About PLENVU:
PLENVU is prescribed for colon cleansing in adults before colonoscopy. It carries risks, including dehydration and changes in blood salts, which may lead to severe health issues. Patients should inform their healthcare provider of all medical conditions and medications before using PLENVU.
Bausch Health Companies Inc., a global pharmaceutical entity, focuses on improving healthcare outcomes in various sectors, including gastroenterology, through its subsidiary, Salix Pharmaceuticals.